Medivir AB, of Stockholm, Sweden, said a Phase I trial has been initiated for MIV-711, a cathepsin K inhibitor to treat bone disorders such as osteoporosis, osteoarthritis and bone metastases. MIV-711 will be administered as single-ascending oral doses to healthy volunteers, followed by daily doses for seven days.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter